ActiFade Systems TM
Producto de salud natural autorizado en Canadá
- Titular
- Preval Group LLC
- NPN o DIN-HM
- 80039263
- Estado
- Licencia activa
- Fecha de licencia
- 29 de enero de 2013
- Fecha de revisión
- No indicada
- Forma
- Crème
- Vía de administración
- Topique
- Tipo de solicitud
- Non traditionnelle
El análisis de dosis orales no se aplica sin una vía exclusivamente oral establecida.
Composición
Composición medicinal no indicada.
Ingredientes no medicinales
Pétrolatum, (p)-hydroxybenzoate de propyle, Parfum, Alcool cétostéarylique, Métabisulfite de sodium, Acide glycolique, Mineral oil, Eau, Stéarate de glycéryle, Acide citrique, Glycérine, Myristate d'isopropyle, Ceteareth-20, EDTA de sodium, Acide ascorbique, DMDM Hydantoin, propylèneglycol, Beurre de karité, Parahydroxybenzoate de méthyle, Extrait de racine de glycyrrhiza uralensis (Réglisse)
Dosis recomendadas en Canadá
| Población | Edad | Cantidad por toma | Frecuencia |
|---|---|---|---|
Adultos Traducido automáticamente del francés. Ver el originalAdultes | No especificada Traducido automáticamente del francés. Ver el originalNon précisée | No especificada Traducido automáticamente del francés. Ver el originalNon précisée | Traducción no disponible. Texto original, idioma: francés. 2 Tous les jours |
Usos autorizados en Canadá
Traducción no disponible. Texto original, idioma: inglés.
For the gradual fading of dark (browning) discoloration in the skin such as freckles, age and liver spots, pigment in the skin that may occur during pregnancy (for use only after childbirth and only if not breastfeeding) or from the use of oral contraceptives.Un uso autorizado en Canadá no es una declaración de propiedades saludables autorizada en la Unión Europea. Consulte el registro de declaraciones de propiedades saludables.
Advertencias en Canadá
Traducción no disponible. Texto original, idioma: inglés.
Cautions and Warnings : Sun exposure should be avoided indefinitely by using a sunscreen agent, a sun block agent, or protective clothing to cover the bleached skin in order to prevent darkening from reoccurring.
Avoid contact with eyes.
If skin irritation develops, use of this product should be discontinued or a health care practitioner should be consulted.
If no improvement is seen after 3 months of treatment, use of this product should be discontinued or a health care practitioner should be consulted.
Depigmentation (lightening) effect of this product may not be noticeable when used on very dark skin.
Do not use on cracked, irritated or inflamed skin.
Some users of this product may experience a mild skin irritation. If skin irritation becomes severe, stop use and consult a health care practitioner.
Keep out of reach of children. Do not use on children under 12 years of age unless directed by a health care practitioner.
For external use only.
If swallowed, get medical help or contact poison control centre right away.
If you have a family history of, have or have had or are at risk of developing cancer, do not use.
To be used only on the advice of a physician.
Do not use this product if you are nursing, pregnant or if you intend to become pregnant within three months of use.
Do not use near mucous membranes. In case of contact, rinse thoroughly with water.
Test for sensitivity. Apply only to small skin surface areas. Discontinue use and consult a physician in case of skin reactions or a blue-black darkening of the skin. Contains sodium metabisulfite, a sulfite that may cause serious allergic type reactions (e.g. hives, itching, wheezing, anaphylaxis, severe asthma attacks) in certain susceptible persons.
Use only as directed. Do not apply over sunburn or irritated skin. A mild transient stinging or minor redness may occur in people with sensitive skin. To test for sensitivity, before treatment, apply to an area of approximately 1 cm of unbroken skin on the inside of the arm. If no irritation occurs within 24 hours, begin treatment for up to 12 weeks. Discontinue use in case of irritation, rash, excessive inflammatory response or if a gradual blue-black darkening of the skin (exogenous ochronosis) occurs. Minor redness is acceptable, but where there is excessive irritation, a rash or other reaction, further treatment is not advised. Severe itching or reddening may occur, in which case the product should be discontinued and the physician notified immediately. The safety of topical hydroquinone use during pregnancy or for children 12 years old or less has not been established. Note: slight darkening of the product is normal and does not affect its potency.
Do not use this product if you have used it or any of its ingredients before and skin sensitivity or irritation has occurred. Hydroquinone is a skin bleaching agent which may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this product.
Close patient supervision is recommended. A bitter taste and anesthetic effect may occur if applied to lips. Treatment should be limited to relatively small areas of the body at one time.Fuente
Ficha oficial de Health Canada, licencia 80039263
Base de datos de productos de salud natural autorizados (BDPSNH), Health Canada: productos autorizados, ingredientes, dosis, usos y advertencias, consultado el 27 de octubre de 2026.
Contient des informations visées par la Licence du gouvernement ouvert – Canada (Santé Canada, BDPSNH)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
La fórmula vendida en Europa con el mismo nombre puede ser diferente. Esta información no sustituye el consejo de un médico o farmacéutico.
Se desconoce la fecha de la prueba de esta lista de ingredientes.
¿Ha cambiado el producto? Fotografíe el envase.